Skip to main content

GRI Bio (US:GRI) — Company Overview, News & Financial Data

GRI Bio logo
GRIGRI Bio
GRI Bio primary media
Company profile

GRI Bio

About

Explore United States companies

GRI Bio (NASDAQ:GRI) is a clinical-stage biotech taking a new approach to inflammatory diseases. They target NKT cells, immune system regulators, to interrupt disease progression. Their lead program, GRI-0621, is a potential treatment for idiopathic pulmonary fibrosis, a serious lung condition. With a library of over 500 compounds, GRI Bio has the potential for a growing pipeline of treatments.

Snapshot

Public USOwnership
2009Year founded
4Employees
La Jolla, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
United States

Products and/or services of GRI Bio

  • Developing therapies: They focus on treatments for inflammatory, fibrotic, and autoimmune diseases.
  • NKT cell targeting: Their approach targets Natural Killer T (NKT) cells to regulate the immune system.
  • Drug pipeline: They have a pipeline of drug candidates, with GRI-0621 being the most advanced.
  • Pre-clinical and clinical trials: Their drugs are currently in pre-clinical and clinical trial phases, not yet available for commercial use.
  • Compound library: They have a library of over 500 proprietary compounds which could fuel future drug development.

GRI Bio executive team

  • Dr. W. Marc Hertz Ph.D.Co-Founder, CEO, President & Director
  • Dr. Vipin Kumar Chaturvedi Ph.D.Co-Founder & Chief Scientific Officer
  • Ms. Leanne M. KellyCFO & Corporate Secretary
  • Dr. Albert Agro Ph.d.Co-Founder & Chief Medical Officer